

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAISHO MICROLINE HOLDINGS LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 00567)

CHANGE OF DIRECTORS; CHANGE OF AUTHORIZED REPRESENTATIVE; AND CHANGE OF PROCESS AGENT

The Board is pleased to announce that with effect from 20 April 2026:

- (1) Mr. WONG Siu Hung, Patrick has tendered his resignation as non-executive Director and the Authorized Representative;
- (2) Mr. LEE Man Kwong has tendered his resignation as the Process Agent; and
- (3) Dr. SUN Jingan has been appointed as an executive Director, an Authorized Representative and a Process Agent.

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND AUTHORIZED REPRESENTATIVE

The board (the “**Board**”) of the directors (the “**Director(s)**”) of Daisho Microline Holdings Limited (the “**Company**”) hereby announces that Mr. WONG Siu Hung, Patrick (“**Mr. WONG**”) has tendered his resignation as non-executive Director, with effect from 20 April 2026 in order to devote more time to focus on his business commitments. Upon the resignation of Mr. WONG, he would also cease to act as the authorized representative of the Company (the “**Authorized Representative**”) as required under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Mr. WONG has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the Stock Exchange or the shareholders of the Company (the “**Shareholders**”).

The Board would like to express its gratitude to Mr. WONG for his services and his valuable contributions to the Board during his tenure of service.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Dr. SUN Jingan (“**Dr. SUN**”) has been appointed as an executive Director with effect from 20 April 2026.

Dr. SUN, aged 52, obtained a bachelor’s degree in investment economics from Shandong University of Finance and Economics in 1996, and a master’s degree and a doctoral degree in finance from Renmin University of China in 1999 and 2006, respectively. Dr. SUN is also a Chartered Financial Analyst (CFA) charterholder.

Dr. SUN is a multi-disciplinary expert in the fields of technological innovation and capital operation, with over 25 years of experience in corporate strategic planning, commercialization of cutting-edge technologies, and corporate governance. In 2024, he founded Jsmart Technologies Limited (“**Jsmart**”) and serves as a director, focusing on the research and development and commercialisation of robotics and embodied AI technologies. Dr. SUN is committed to the deep integration of cutting-edge technology and innovative business models, and has demonstrated outstanding vision and leadership in the market-oriented application of intelligent robotics, technology asset operations, and industrial chain mergers, acquisitions and integration. Prior to this, from 1999 to 2021, Dr. SUN held senior management positions in a number of renowned financial and investment institutions, accumulating profound experience in global strategy and business management. His principal work experience includes serving as director and general manager of CITIC Capital (Qingdao) Investment Management Co., Ltd., director and general manager of Value Partners Private Equity Fund, investment director of China Shipping Fund, vice president of CITIC Capital Holdings Limited, and manager at China CITIC Bank and China CITIC Bank (International) Limited.

Dr. SUN has entered into a service contract with the Company under which he acts as an executive Director for an initial term of three years which is renewable automatically for successive terms of one year each commencing from the day next after the expiry of the then current term, subject to retirement by rotation and re-election at the general meeting of the Company in accordance with the Bye-Laws of the Company, unless and until terminated by either party giving to the other not less than one month’s notice in writing. Pursuant to such service contract, Dr. SUN is entitled to a fixed salary of HK\$25,000 per month. Such director’s remuneration is determined by the Board based on the recommendation of the remuneration committee of the Company with reference to his duties and responsibilities with the Company and the remuneration policy of the Company.

Jsmart is jointly owned by two shareholders, Dr. SUN and Ms. MA Ying who is his spouse, and Dr. SUN is the sole director of Jsmart. Jsmart is the beneficial owner of 280,000,000 shares of the Company (“**Shares**”), representing approximately 17.36% of the entire issued share capital of the Company as at the date of this announcement, and Jsmart is the substantial Shareholder of the Company. As Jsmart is controlled by Dr. SUN and is owned by Dr. SUN and his spouse jointly, Dr. SUN is deemed to be interested in the 280,000,000 Shares held by Jsmart within the meaning of Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, Dr. SUN (i) has not held any directorship in any listed public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any other major appointment or professional qualification; (iii) does not have any interest or is not deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong); and (iv) does not have any relationship with any other directors, senior management or substantial or controlling Shareholders or its subsidiaries.

Save as disclosed above, the Board is not aware of any matter in relation to the appointment of Dr. SUN that needs to be brought to the attention of the Shareholders and/or the Stock Exchange nor any information to be disclosed pursuant to Rule 13.51(2) of the Listing Rules on the Stock Exchange.

The Board would like to take this opportunity to welcome Dr. SUN to the Board.

CHANGE OF AUTHORIZED REPRESENTATIVE

The Board further announces that following the resignation of Mr. WONG as the Authorized Representative, Dr. SUN has been appointed as the Authorized Representative with effect from 20 April 2026.

CHANGE OF PROCESS AGENT IN HONG KONG

The Board further announces that Mr. LEE Man Kwong has tendered his resignation as the authorized representative of the Company under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) for the acceptance of service of process and notices in Hong Kong (the “**Process Agent**”), and Dr. SUN has been appointed as the Process Agent with effect from 20 April 2026.

By Order of the Board
Daisho Microline Holdings Limited
LEE Man Kwong
Chairman

Hong Kong, 20 April 2026

As of the date of this announcement, the Board comprises two executive Directors, namely, LEE Man Kwong, SUN Jingan, one non-executive Director, namely, YAU Pak Yue and three independent non-executive Directors, namely, CHAN Yau Ching, Bob, LEUNG Hoi Ming and LIN Ying.